Your browser is no longer supported. Please, upgrade your browser.
Settings
RFL Rafael Holdings, Inc. daily Stock Chart
RFL [NYSE]
Rafael Holdings, Inc.
Index- P/E- EPS (ttm)-0.79 Insider Own0.70% Shs Outstand12.33M Perf Week4.57%
Market Cap107.27M Forward P/E- EPS next Y- Insider Trans- Shs Float9.79M Perf Month0.00%
Income-9.20M PEG- EPS next Q- Inst Own38.60% Short Float0.45% Perf Quarter-5.23%
Sales4.40M P/S24.38 EPS this Y- Inst Trans-0.21% Short Ratio2.55 Perf Half Y3.69%
Book/sh8.66 P/B1.00 EPS next Y- ROA-12.10% Target Price- Perf Year-
Cash/sh3.28 P/C2.65 EPS next 5Y- ROE-15.60% 52W Range3.05 - 10.31 Perf YTD77.55%
Dividend- P/FCF- EPS past 5Y- ROI-9.20% 52W High-15.62% Beta-
Dividend %- Quick Ratio50.00 Sales past 5Y- Gross Margin- 52W Low185.25% ATR0.32
Employees14 Current Ratio50.00 Sales Q/Q-25.00% Oper. Margin-87.30% RSI (14)52.63 Volatility3.92% 3.46%
OptionableNo Debt/Eq0.00 EPS Q/Q- Profit Margin- Rel Volume0.85 Prev Close8.43
ShortableYes LT Debt/Eq0.00 EarningsOct 15 BMO Payout- Avg Volume17.21K Price8.70
Recom- SMA202.44% SMA500.95% SMA2002.22% Volume14,609 Change3.20%
Nov-06-18 08:55AM  Rafael Pharmaceuticals Appoints Vice President, Manufacturing and CMC Regulatory Affairs and Vice President of Regulatory Affairs to Strengthen Development of CPI-613 GlobeNewswire
Oct-15-18 09:05AM  Rafael Holdings Reports Fourth Quarter and Full Fiscal Year 2018 Results PR Newswire
08:55AM  Rafael Pharmaceuticals to Present at BIO Investor Forum 2018 GlobeNewswire
Oct-09-18 08:55AM  Rafael Pharmaceuticals to Present at BIO Investor Forum 2018 GlobeNewswire
Oct-05-18 08:30AM  Rafael Holdings to Report Fourth Quarter and Full Fiscal Year 2018 Results PR Newswire
Sep-21-18 12:45PM  Rafael Holdings to Present at Sidoti Fall 2018 Investor Conference PR Newswire
Sep-07-18 08:30AM  Rafael Holdings Increases Stake in Rafael Pharma PR Newswire
Aug-16-18 10:55AM  Rafael Pharmaceuticals Receives FDA Orphan Drug Designation of CPI-613 for the Treatment of Peripheral T-Cell Lymphoma (PTCL) GlobeNewswire
Aug-13-18 11:15AM  Rafael Pharmaceuticals Announces Activation of Second Clinical Trial Site for the Phase I Study of CPI-613 in Patients with Relapsed or Refractory T-Cell Lymphoma GlobeNewswire
Jul-09-18 10:39AM  5 Spinoff Stocks That Outperform Their Parents InvestorPlace
Jul-06-18 08:30AM  Rafael Holdings to Ring the NYSE Opening Bell PR Newswire
Jun-11-18 08:30AM  Rafael Holdings Reports Third Quarter Fiscal Year 2018 Results PR Newswire
Jun-07-18 03:12PM  Rafael Holdings to Report Third Quarter Fiscal Year 2018 Results PR Newswire
May-17-18 09:47AM  Should You Be Concerned About Rafael Holdings Incs (NYSEMKT:RFL) Investors? Simply Wall St.
Mar-27-18 08:30AM  IDT Completes Spin-Off of Rafael Holdings PR Newswire
Rafael Holdings, Inc. holds commercial real estate assets. The company, through its subsidiaries, focuses on the development and commercialization of oncology drugs. Rafael Holdings, Inc. is based in Newark, New Jersey.